A detailed log file analysis was performed by the manufacturer.On the reported date of event the described reboot could be confirmed- whereby the root cause could not be determined from the records.No further reboots were recorded, neither before nor after the date of event.The replaced pba therapy control unit m16.2 including the cf were assembled to a lab device and operated for 8 days while in total 1 reboot of less than 15 seconds was recorded.The related error codes filed in the log were similar to those from the submitted logfile.During a functional test of the m16.2 board no hardwar failure could be identified.Also the investigaton of the cf card did not reveal any functional limitation.Although no hardware failure was identified the therapy control unit m16.2 can be regarded as root cause of the reported symptom.In case of a reset of the processors of the therapy control unit m16 therapy is discontinued for a maximum of 15 seconds, before therapy will be resumed with the latest valid settings.For the current case the device returned to operation after 14 seconds.After replacement of the m16.2 board incl.Cf card, the device was tested and returned to use without further problems reported.The number of similar cases, related to the same root cause, is within the expected range of the respective risk assessment and thus accepted.The field failure rate is subject to permanent monitoring by the responsible product quality board and is rated as acceptable.
|